Evaluation and Management of Lower Back Pain in Oncological Patients by Joshua E. Schroeder et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Evaluation and Management of Lower  
Back Pain in Oncological Patients 
Joshua E. Schroeder1, Yair Barzilay1, Amir Hasharoni1,  
Leon Kaplan1, José E. Cohen2 and Eyal Itshayek2  
1Departments of Orthopedic Surgery, 
Hadassah—Hebrew University Medical Center Jerusalem,  
2Departments of Neurosurgery,  
Hadassah—Hebrew University Medical Center Jerusalem,  
Israel 
1. Introduction 
Back pain is one of the most common complaints that brings patients to be examined by a 
physician (Moore, 2010). Pain may originate from a variety of tissues, including 
intervertebral disks, vertebrae, ligaments, neural structures, muscles, and fascia, or present 
as referred pain from adjacent pathology, such as peptic ulcers, pancreatitis, pyelonephritis, 
aortic aneurysm, and more (Henschke, et al., 2009). Nonspecific low back pain is typically 
managed with symptomatic care and physical therapy, with up to 90% of patients 
improving substantially over 3 months. It is such a common condition that the American 
College of Physicians has issued guidelines with a mandate against imaging patients for the 
first month after pain onset (Chou, 2010).  
Serious, life-threatening diseases are uncommon causes of back pain; malignancy, 
ankylosing spondylitis, and infection together account for less than 5% of back pain cases in 
a typical primary care practice (Dagenais, et al., 2010). However, missing such a critical 
diagnosis represents a serious concern for every practitioner; thus complaints of back pain 
often lead to multiple imaging studies and consultations (Venkitaraman, et al., 2010). 
The spine is one of the most common sites of metastasis with close to 20,000 cases of spine 
metastases arising each year in the United States (Sciubba, et al., 2009). The most common 
primary tumors in patients with metastases are breast, lung, prostate, and kidney cancer 
(Guillevin, et al., 2007). In close to 15% of oncology patients, the primary presenting 
symptoms of malignancy are related to spinal metastases. In these patients, the most 
common underlying pathology is lung cancer, followed by breast cancer in females and 
prostate cancer in male patients (Chamberlain & Kormanik, 1999). 
When the patient’s history is taken properly, a thorough physical examination is conducted, 
and appropriate diagnostic tests are performed, the physician can determine with a high 
level of accuracy whether an individual patient is suffering from nonspecific ("simple") back 
pain, or whether an underlying, potentially catastrophic disease is triggering the pain (Bach, 
et al., 1990). 
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In taking the patient’s history, one should try to define specific characteristics of the pain. Is 
this radicular or axial back pain? Is the pain worse at night or in the morning? Is the pain 
mechanical in nature or constant? Is it progressing? The examining physician should also 
look for signs and symptoms of systemic disease, such as fatigue, night sweats, weight loss, 
and changes in bowel habits. Personal habits such as smoking, alcohol consumption, or 
drug use should be identified as a potential clue to the underlying pathology. 
In a patient with a known history of cancer, the situation is quite different. Each new ache 
and bump might lead to the fear of a metastasis, and patients will thus be highly sensitive to 
changes. On the other hand, ignoring symptoms or assuming that they are normal side 
effects of medical treatment may lead a missed diagnosis and delayed treatment, with the 
potential of significantly shortening a patient’s life expectancy or greatly reducing the 
quality of remaining life (Verbeeck, 2004). Sadly, although the awareness to the risk of spinal 
metastases is high, even in patients at high risk, progression, with catastrophic consequences 
can occur during a drawn out diagnostic process (Cole & Patchell, 2008; Hagelberg & Allan, 
1990; Loblaw, et al., 2005). Although a high level of suspicion may lead to higher rates of 
imaging in these patients, any back pain in a patient with a history of malignancy should be 
considered as suspicious for spinal metastases and should be fully investigated. 
We aimed to review the essential skills required for diagnosis of the etiology of back pain, 
and to outline basic elements of treatment in patients presenting with metastatic disease to 
the spine. 
2. Making the diagnosis 
2.1 Characteristics of benign back pain 
Defining a patient's pain is a hard task. Pain is subjective. The way in which pain is 
experienced, tolerance for pain, the language used to describe it, and its impact on quality of 
life differ from patient to patient and from culture to culture. Pain can be affected by 
medications, comorbidities, prior treatments, and by the patient’s life situation and mental 
state (Florence, 1981). With these points in mind, specific information can enable a skilled 
diagnostician to differentiate metastatic pain from benign back pain.  
Benign back pain often arises from a specific event, is relieved by rest and lying down, and 
increases with activity such as lifting, sneezing, laughing, and the Valsalva maneuver 
(Lishchyna & Henderson, 2004). It is most commonly focal, with adjacent spasm of the 
lumbar muscles and buttocks. Benign back pain generally subsides several weeks after 
injury, and can be managed effectively with non-narcotic analgesics and physical therapy 
(Ladeira, 2011). Patients with benign pain may experience several relapses, but generally 
pain remits between attacks. In a portion of patients (up to 7%) benign pain becomes 
chronic, however a discussion of chronic back pain is beyond the scope of this chapter. 
2.2 Characteristics of metastatic back pain 
In contrast, pain caused by spinal metastases is typically persistent and progressive, and is 
not alleviated by rest. Often pain is worse at night, awakening the patient from sleep. This 
pain is typically focal at the level of the lesion, progresses over several days or weeks, and 
may be associated with neurological signs indicating pressure on the neural spinal elements 
(Bach, et al., 1990). 
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A spinal mass can cause one of several forms of back pain. Localized pain is confined to the 
region of the spine affected by the tumor. This type of pain presents when a metastasis that 
originally developed in the bone marrow extends to stretch the periosteum or invades soft 
tissues, triggering pain from the nerve roots or signaling instability in a specific spine 
segment (Cole & Patchell, 2008). 
A second form of pain is radicular pain due to nerve root compression or invasion. This pain 
is also typically worse at night and when the patient is recumbent, due to lengthening of the 
spine and distension of the spinal epidural venous plexus. This pain is often made worse by 
a Valsalva maneuver or other stretching movement of the spine or lower limb. The pain is 
usually dermatome-linked and may be associated with weakness of the muscles innervated 
by this nerve root (Cole & Patchell, 2008). If more than one nerve root is involved, the pain 
might extend to more than one dermatome. 
A third type of pain appears when a pathologic fracture is present. This pain is generally 
focal, associated with instability, and progressive. It will worsen with movement. In the case 
of a fracture, the patient may remember a specific event or time when the pain began. It can 
be debilitating, necessitating the use of large doses of narcotics or preventing the patient 
from sitting or walking (Smith, 2011). These fractures may also lead to neurological changes 
due to neural element compression (Shaw, et al., 1989).  
Sadly, not all patients with spinal metastasis present with early back pain. Many times a 
metastasis, like other slowly evolving conditions, becomes symptomatic only when there is 
neural compression. In this case, the patient will come to medical care only when there is 
cord compression, with imminent risk of losing mobility and control of the bowels. This late 
presentation is associated with a lower probability of neurological recovery, and a high rate 
of morbidity and mortality (Sundaresan, et al., 1995). 
2.3 Physical examination 
As is the case with any diagnostic process, the physical examination begins when the patient 
walks through the door. The patient’s general appearance, nutritional state, walking pattern, 
and general habitus can be assessed during the walk to the examination bed. It is thus 
important for the physician to be positioned to watch the patient’s entry, and to be alert to 
these details. 
A general examination should be performed, including clinical examination of the breasts, 
lungs, abdomen, thyroid, and prostate, in the appropriate setting. After the general 
examination, a thorough orthopedic examination should be performed to evaluate any 
limitation in movement or impairment due to metastatic disease in other locations. The 
spine should be examined to identify sites of focal tenderness and assess range of motion. 
Signs of spinal instability or neural compression should be evaluated, and a full 
neurological examination should be performed, including assessment of strength, deep and 
superficial sensation, and proprioception, as well as deep tendon and pathological reflexes 
(Winters, et al., 2006). In order to try to locate the specific location of the lesion, sensory and 
motor levels should be assessed and documented. 
Physical examination should be repeated periodically to allow early detection of any 
pathological motor or sensory findings or abnormal reflexes or any signs suggesting spinal 
instability or pathological fracture (Bates & Reuler, 1988).  
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With findings from the physical examination in hand, the physician should have an 
understanding of the pathology, and whether it is pointing towards metastatic spread of the 
primary disease to the spine. The next steps in diagnosis or treatment are determined by 
these findings.  
2.4 Blood work  
If the history and physical examination leads to the suspicion that the patient’s pain could 
originate from something more severe than common backache, blood work is mandated. If 
cancer is suspected, initial tests should include a complete blood count, a full chemistry 
panel including calcium and phosphate levels (de Mello, et al., 1983), evaluation of the 
erythrocyte sedimentation rate, and C-reactive protein levels (Elsberger, et al., 2011). If 
laboratory studies reveal anemia, thrombocytopenia hypercalcaemia, or elevated levels of 
alkaline phosphatase, concern should increase (Nieder, et al., 2010). Specific markers for 
prostate and breast cancer should be tested, as well as urine and blood protein 
electrophoresis if gammopathy (multiple myeloma or plasmacytoma) is suspected 
(Scharschmidt, et al., 2011). 
A blood smear or a bone marrow biopsy may be indicated if hematological disease is 
suspected (Raje & Roodman, 2011). 
2.5 Imaging 
Metastases generally appear in more than one anatomic location. They can be in the brain, 
soft liver, lungs, or lymph nodes. In the skeleton, the third most common location for tumor 
spread, lesions may be found in the vertebrae, pelvis, proximal parts of the femur, ribs, 
proximal part of the humerus, and skull (Ratanatharathorn, et al., 1999). If a spinal 
metastasis is suspected, it is important to perform a full workup, both to identify the 
primary lesion and to detect other metastases. 
2.5.1 X-ray 
Simple X-rays of the spine are considered to be the first and most attainable imaging study. 
If obtained, they should be complimented with a chest X-ray for a preliminary search for 
lung involvement, however neither spinal nor lung tumors are well visualized on 
radiographs until the malignancy has advanced significantly (Nielsen, et al., 1991). Lateral 
X-ray may show vertebral body collapse. AP views may demonstrate pedicle erosion (the 
“winking owl” sign) or evidence of a paraspinal mass (Fehlings & Rao, 2000).  
In cases where the physician has a high degree of suspicion towards metastatic spine 
disease, a more expeditious approach to diagnosis should be taken using advance imaging 
techniques such as CT or MRI (Black, et al., 1996). In these patients X-ray may be used as a 
complimentary study, since images obtained standing and dynamic X-rays can provide a 
better understanding of sagittal balance and stability of the diseased spine.  
2.5.2 Computed Tomography 
Computerized tomography (CT) has higher sensitivity and specificity than X-ray. Multislice 
CT (MDCT) systems facilitate a single rapid study of the chest-abdomen-pelvis. Osteolytic, 
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sclerotic, and mixed lesions are depicted well on CT scans, as are lesions involving the 
viscera and vascular anatomy. However, while 16/64 row MDCT provides excellent image 
quality and clear assessment of bony structures, metastatic lesions without significant bone 
destruction may be missed (Buhmann-Kirchhoff, et al., 2009). CT scans are also associated 
with relatively high quantities of radiation, limiting the number of screening studies that 
should be performed, especially in a younger population (Huda & He, 2011). In addition, 
the differential diagnosis between a malignant process versus osteoporotic or degenerative 
disease can be challenging in the spinal column (Chassang, et al., 2007). CT findings that 
suggest metastatic disease include destruction of the anterolateral or posterior vertebral 
cortex, destruction of one or both pedicles, an epidural mass, and presence of a focal 
paraspinal soft tissue mass (Fehlings & Rao, 2000; Laredo, et al., 1995).  
 
            A     B    C 
Fig. 1. Spinal metastasis to the thoracic and lumbar spine. A 74-year-old female with a 
history of gastrointestinal stromal tumor (GIST) presented with right leg sciatic pain and 
weakness. (A) Sagittal CT revealed an osteolytic metastasis in the vertebral body of T7, L1, 
and L2 (arrows). The L2 metastasis was most prominent, producing compression of the 
cauda equina. (B) Axial CT through the body of L2 demonstrating the soft tissue mass, 
which has created a cavity in the vertebral body, narrowed the spinal canal and created 
pressure on the cauda equina. (C) X-ray after transpedicular excision of the lesion shows 
reconstruction of the vertebral body with polymethylmethacrylate (PMMA) and L1-L3 
posterolateral fixation with transpedicular screws and rods. The patient experienced 
immediate and sustained pain relief, with recovery of her previous strength. Two weeks 
after surgery she was treated with adjuvant EBRT.  
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2.5.3 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is gold standard for evaluating spinal tumors. It depicts 
vertebral bone marrow infiltration by tumor cells as well as soft tissue masses in and around 
the spinal column. Bone marrow invaded by a neoplasm is characterized by increased 
cellularity, resulting in a decreased signal on T1-weighted images and a high signal on T2-
weighted images, thus differentiating it from normal marrow tissue (Loblaw, et al., 2005). 
Intravenous gadolinium further increases the contrast between tumor and normal tissues 
(Loughrey, et al., 2000). MRI has been shown to detect up to 98.5% of vertebrae with 
metastatic disease, including both osteolyitic and osteoblastic lesions. This high level of 
detection is not compromised by osteoporosity (Buhmann-Kirchhoff, et al., 2009).  
However, MRI is a costly, time consuming exam, limiting its efficacy in patients who have 
difficulty lying down without moving for long periods of time and those who are 
claustrophobic or morbid (Eshed, et al., 2007). In addition, it may be difficult to differentiate 
between osteoporotic compression fracture and metastatic disease, especially if a fracture 
co-exists. Signs that characterize malignant vertebral collapse include ill-defined vertebral 
margins, abnormal signal involvement of the pedicle, a marked and heterogeneous MR 
enhancement pattern, and the presence of an irregular nodular-type paraspinal vertebral 
lesion (Shih, et al., 1999). Using of different diffusion coefficients may assist correctly 
identifying this deferential diagnosis (Chan, et al., 2002).  
 
    A         B 
Fig. 2. MRI of the lumbar spine. A 42-year-old male presented with cauda equina 
syndrome due to an epidural metastasis to the lumbar spine from a synovial sarcoma 
originating in the left lower limb. (A) Preoperative T2-weighted sagittal MRI demonstrating 
a metastasis to the L4 vertebral body invading the epidural space and compressing the 
thecal sac (arrow). The patient underwent laminectomy and resection of the epidural mass. 
(B) Postoperative T2-weighted sagittal MRI showing post-laminectomy decompression of 
the thecal sac. 
www.intechopen.com
 Evaluation and Management of Lower Back Pain in Oncological Patients 
 
97 
2.5.4 99Tc bone scan 
With the exception of purely lytic tumors such as myeloma, eosinophilic granuloma, and 
renal cell carcinoma, 99mTc-methylene diphosphonate (MDP) bone scan has good 
sensitivity to tumors, is widely available, and has a relatively low cost, with the ability to 
scan the entire skeleton in a single study. It can be performed as a flat two dimensional 
exam or, incorporating more advanced single-photon emission computed tomography 
(SPECT) technology, with true 3D information. Bone scans have moderate sensitivity in the 
spine and pelvis (Steinborn, et al., 1999). Sensitivity to detection of spine metastasis can be 
significantly improved by the combination of bone scan and SPECT imaging capabilities 
(Schirrmeister, et al., 2001). Bone scans combined with SPECT may depict spinal lesions as 
well as metastases in other bones or organs, and provide some indication of the site of the 
primary tumor in cases where this is not known. The main drawback to these studies is 
exposure to high levels of ionizing radiation and a lower rate of detection when compared 
with MRI (Sedonja & Budihna, 1999).  
2.5.5 PET/CT 
FDG-PET/CT studies in oncology utilize labeled glucose with the tracer fluorine-18 (F-18) 
fluorodeoxyglucose (FDG), in combination with MDCT, to provide the benefits of metabolic 
and anatomic imaging in a single study. FDG is a glucose analog that is taken up by glucose-
using cells and phosphorylated by hexokinase in the mitochondria. Increased tumor [18F]-
FDG uptake is depicted by positron emission tomography (PET), although proliferative 
activity is also broadly related to the number of viable tumor cells. When glucose is 
metabolized, the tissue incorporates the radioactive isomer, increasing local particle 
emission and producing a high intensity signal on PET/CT images (Young, et al., 1999).  
PET-CT is a sensitive method for assessment of bone and bone marrow metastases, as well 
as vertebral and extravertebral skeletal masses. It is sensitive for osteolytic and osteoblastic 
metastasis and depicts early malignant bone-marrow infiltration (Kruger, et al., 2009). It 
provides precise localization and is sensitive to accompanying soft tissue metastases in the 
lung, liver, lymphatic system, and elsewhere (Metser, et al., 2004; Nguyen, et al., 2007). Low 
resolution PET scans are combined with the high resolution of thin slice CT, for exquisite 
depiction of even small metastases in early stages. PET/CT has higher sensitivity and 
specificity compared to bone scintigraphy or CT in the detection of skeletal metastases 
(Kruger, et al., 2009), however the rate of false-positive findings that require follow-up 
imaging with other modalities is also higher (Kuo & Cheng, 2005). 
3. Cord compression 
Discussions of metastatic epidural cord compression usually focus on the thoracic spine. 
Although the spinal cord usually ends in the lumbar spine between L1 and L2 in adults, up 
to 20% of metastatic cord compression occurs at these levels; thus lumbar cord compression 
must also be discussed. 
Metastatic spinal cord compression (SCC) occurs in 5–10% of patients with cancer (Bach, et 
al., 1990). It is a true emergency, because delay in diagnosis and treatment may result in 
permanent neurological impairment. SCC is caused by direct compression of metastasis or 
primary tumors invading the vertebral bodies, breaking through the cortex, and 
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compressing the vertebral canal and nerve roots (Bilsky, et al., 2000). The most commonly 
affected site is the thoracic spine, which is also the area in which the canal is the tightest, 
leaving little space for movement of the cord. Breast cancer is the most frequent primary 
malignancy associated with SCC, followed by lung, prostate, and renal cancers (Byrne, 
1992). However, SCC is also common in patients with hematological tumors such as 
lymphoma and myeloma. SCC is the initial manifestation of a metastatic spread of a tumor 
in approximately 20% of cancer patients; in patients with lung cancer the rate of SCC at first 
presentation climbs to 30% (Chahal, et al., 2003). In most of the cases of SCC, back pain has 
been present for several months before detection, but was ignored by the patient and 
caretakers (Byrne, 1992).  
The most important factor in determining the post-treatment outcome is pretreatment 
ambulatory function of the patient. Late presentation with neurological deficits, including 
bowel or bladder dysfunction, is often associated with irreversible paraplegia. In recent 
series, 74-100% of patients who were ambulatory before surgery retained the ability to walk 
after decompression, and 57-82% of nonambulatory patients regained ambulation (Bilsky, et 
al., 2009). However ambulation at surgery remains a key determinant of outcome, therefore, 
urgent investigations must be performed to facilitate treatment before function is lost. 
4. Treatment 
4.1 Medical management of pain 
Basic pain control is achieved by the use of narcotics and non-narcotic analgesics. In patients 
with back pain due to metastases, pain control is one of the most important goals in 
management, as the life expectancy of the patients is limited (Padalkar & Tow, 2011). Sadly, 
despite this concept, most patients are undertreated for pain, which causes a significant 
reduction in quality of life (Cleeland, 2006). Two types of pain needed to be addressed when 
dealing with medical management of the metastatic patients, the constant pain of the 
metastasis and an acute episode of sharp pain, known as “breakthrough pain” (Lipton, 
2011).  
The first line of treatment in patients with mild low back pain is the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) and acetaminophen. These agents may provide adequate 
pain relief. There have been nine trials indicating that the use of NSAIDS provides pain 
relief in bone metastasis, including one showing that NSAIDS (specifically COX-2 inhibitors) 
assist in tumor control as well (Smith, 2011). Acetaminophen is preferred in patients with 
thrombocytopenia, renal dysfunction, those receiving nephrotoxic agents, and those at risk 
for gastrointestinal bleeding. In patients with liver dysfunction, NSAIDs are preferred for 
mild pain (Hitron & Adams, 2009)  
In patients who need the next level of treatment for their low back pain, opioid therapy 
should be added. Common protocols begin with low doses of immediate-release short-
acting agents (i.e. morphine), with reassessment for the level of effect every 1 to 2 hours. 
After 24 hours of pain control on a short-acting regimen, patients should be converted to a 
long-acting agent such as sustained-release morphine, oxycodone, fentanyl, or methadone 
for basal control. Patients who are opioid tolerant should begin with higher doses of short-
acting agents, with the higher dose compensating for shorter duration of effect. If a patient is 
already using a long-acting product, this should be continued. A bowel regimen with a 
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stimulant plus stool softener should be initiated to prevent constipation from opioid use. 
Care must be taken to avoid misuse and abuse of opioids, even in cancer patients 
(Manchikanti, et al., 2010). 
Adjunct agents such as anticonvulsants (e.g., gabapentin, lamotrigine, topiramate), tricyclic 
antidepressants (e.g., amitriptyline, imipramine, desipramine, nortriptyline), venlafaxine, 
duloxetine, or topical analgesics (e.g., lidocaine or capsaicin) may also help to reduce 
neuropathic pain caused by nerve compression (Hitron & Adams, 2009). 
In cases of breakthough pain, oral transmucosal fentanyl and transdermal patches have been 
shown to be an effective treatment for pain including sharp pain episodes, yielding a more 
rapid onset of relief. In cases where patients developed tolerance towards opioid narcotics, 
the use of anesthetics, such as ketamine can provide adequate pain relief (Chazan, et al., 
2008).  
The use of cannabinoids as an alternative or to augment narcotics has become popular, 
primarily for light-to-intermediate pain. Three cannabinoids, all a combination of the delta-
9-tetra-hydrocannabinol and cannabidiol cannabinoids from the Cannabis sativa plant, are 
available on the market. Sativex, a cannabinoid medication, has recently received approval 
as an adjuvant medication for the treatment of cancer pain in North America. It is a 
sublingual (mouth) spray that can be titrated up to the most effective dose (Bonneau, 2008). 
Other forms of cannabinoids treatment include smoking marijuana, or ingestion of oils or 
even cookies with insertion of active cannabinoid components. In our experience, “cannabis 
cookies” have provided relief or reduction in chronic pain levels for some cancer patients. 
The use of cannabinoids is indicated in cancer pain with a neuropathic component that is 
not adequately controlled with opioids. Cannabinoids are not suitable as a single medication 
in spine metastasis.  
4.2 Steroids  
Steroids are commonly prescribed in patients with metastatic bone disease. Steroids reduce 
edema and have been shown to reduce the size of metastases from tumors of hematological 
origin, and occasionally breast cancer (Cole & Patchell, 2008). They have also been shown to 
have a rapid analgesic effect (Bonneau, 2008). However, they are associated with side 
effects, such as wound dehiscence, gastric ulcers, rectal bleeding, psychosis, and diabetes 
mellitus, and may increase susceptibility to infections (Shih & Jackson, 2007).  
An early study (Greenberg, et al., 1980) demonstrated quick and significant pain reduction 
in patients treated with steroids. A subsequent randomized trial (Vecht, et al., 1989) 
compared the effect of 10 mg IV dexamethasone versus 100 mg IV followed by 16 mg daily 
orally and found no differences between the conventional and high-dose group on pain, 
ambulation, or bladder function. Both the conventional and high-dose regimens provided 
significant pain relief. 
A randomized, controlled trial (Sorensen, et al., 1994) studied the administration of 96 mg of 
IV dexamethasone followed by 96 mg orally for 3 days and then tapered in 10 days, with 
subsequent radiotherapy, versus radiotherapy as a single modality in the treatment of SCC. 
Steroid treatment provided a statistically significant improvement in ambulation at 3 to 6 
months, albeit with increased side effects, including psychoses and gastric ulcers requiring 
surgery. The effect of dexamethasone on pain reduction was not addressed.  
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Currently there are no absolute guidelines for steroid treatment in patients with back pain 
due to spinal metastases. The decision of whether to treat, as well as steroid dose are 
determined by the treating physician. In cases of SCC, steroid treatment is given as an 
adjuvant to surgery or to chemo- or radiotherapy, and not as sole treatment modality.  
4.3 Bisphosphonates 
Bisphosphonates are pyrophosphate analogues. The bisphosphonates strongly bind 
hydroxyapatite crystals in bone, preventing the creation of the ruffle border of the 
osteoclasts that prevent bone resorption. In addition, bisphosphonates induce osteoclast 
apoptosis (Li, et al., 2011).  
The rationale for using drugs such as bisphosphonates in patients with metastatic cancer is 
that osteoclasts, as the mediators of bone absorption, are often activated by the tumors and 
thus allow metastatic invasion into the medulla of the vertebrae. Preventing such activity 
may reduce metastatic invasion and spread (Orita, et al., 2011). In addition, by inhibiting 
bone resorption, a secondary correction of hypercalcaemia and hypercalciuria will be 
achieved (Woodward & Coleman, 2010). 
Most importantly, the use of bisphosphonates reduces pain and the occurrence of fracture, 
as well as the development of new osteolytic lesions and, as a consequence, improves 
patients’ quality of life (Fleisch, 1991). Compounds that are commercially available for use in 
tumor-induced bone disease are, in order of increasing potency, etidronate, clodronate, 
pamidronate, and alendronate. 
Van Holten-Verzantvoort et al found a significant reduction in morbidity from bone 
metastases in pamidronate-treated breast cancer patients, with a 30–50% reduction of pain 
and lower rate of new pathological fractures (van Holten-Verzantvoort, et al., 1991). 
Thurlimann et al showed that pain relief was achieved in about 30% of patients who 
received pamidronate every 4 weeks (Thurlimann, et al., 1994). 
Side effects from bisphosphonates, including transient low grade fever, nausea, myalgia, 
gastrointestinal side-effects, bone pain, and mild infusion-site reactions, are usually 
minimal. More rarely, osteonecrosis of the jaw and long bone “frozen bone” fractures due to 
long term use have been reported (Kim, et al., 2011; Mercadante, 1997). 
A meta-analysis (Fulfaro, et al., 1998) concluded that bisphosphonates, and in particular IV 
pamidronate, are an important therapeutic tool in association with other therapeutic 
modalities for the treatment of metastatic bone disease with marked osteolysis, such as 
multiple myeloma and breast cancer. The authors did not evaluate the impact on back pain, 
but looked at the general effect of bisphosphonates on bone metastases.  
4.4 Chemotherapy 
As is the case with metastatic disease in other locations, the long-term control of spine 
metastases entails systemic chemotherapy. The type of treatment and its duration largely 
depend on the tumor histology and specific tumor receptors. The full treatment plan should 
be determined by a team of oncologists, spine surgeons, and radiotherapists, balancing the 
different modalities of treatment with the side effects and complications. 
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Hoy et al showed that many patients experience pain relief with chemotherapy, even in 
cases where there is no objective tumor response (Hoy, 1989). Although palliative, the exact 
benefit of chemotherapy is difficult to measure. Potential indications for palliative 
chemotherapy include symptoms due to metastatic disease, hypercalcemia, bone marrow 
infiltration, and clinical conditions known to be associated with bone or spine metastases. 
As patients are mainly treated with a combination of therapies, the exact effect of the 
response in the bone is more difficult to assess (Lote, et al., 1986). 
In tumors that react quickly to chemotherapy, as in testicular cancers, lymphoma, or 
myeloma, administration of chemotherapy can have a pronounced effect in reducing back 
pain (Samoladas, et al., 2008). In tumors where the response to chemotherapy is slower, as in 
pancreatic cancer, pain reduction parallels the decrease in pressure exerted on spinal 
structures as the tumor slowly diminishes in size (Takuma, et al., 2006). However, in very 
advanced cancer patients there is little justification for using chemotherapy because of its 
toxicity (Bruera, 1993). 
Hormonal therapy, based on the principle of depriving tumor cells of the growth stimulus 
induced by hormones that change the hormonal environment, may be beneficial in breast, 
prostate, and endometrial cancers (Wood, 1993). This treatment has a lower toxicity profile 
compared to chemotherapy, and should be the first therapeutic modality if possible. 
Dearnaley showed that hormonal therapy provides sustained symptom relief in patients 
with widespread painful bone metastases from prostatic cancer (Dearnaley, 1994). Cresenda 
et al showed that the combination of hormonal therapy with radiation for spinal metastasis 
reduces pain in 77% of patients (Cereceda, et al., 2003). There are no data regarding the 
impact on pain from the isolated use of hormonal therapy in patients with spinal metastasis. 
4.5 Radiation-based treatment 
Radiotherapy has served as a cornerstone for the treatment of bone metastases since it was 
introduced in the 1950s. Its benefits include reduction of pain and neurological 
complications arising from spinal cord compression. Radiation-based treatment is 
undergoing a revolution, with new stereotactic techniques for single-shot or fractionated 
treatment showing good results. However the mainstay of radiation-based treatment is 
external beam radiation therapy (EBRT) (Cole & Patchell, 2008; Harel & Angelov, 2010). 
4.5.1 External beam radiation therapy 
The exact pathophysiology of tumor response to radiotherapy is not fully understood, 
however EBRT can lead to rapid reduction in the tumor size, sometimes within 24 hours, 
decreasing local periosteal nerve stimulation. EBRT is typically given from a posterior field 
to the affected vertebra(e), with radiation delivered to a treatment area including one 
vertebral body above and one below to compensate for daily variations in patient setup.  
A meta-analysis (Agarawal, et al., 2006), reported that over 40% of patients with bone 
metastases treated with radiation achieved at least a 50% reduction in pain, however fewer 
than 30% experienced complete pain relief at 1 month.  
In cases of SCC, when surgery is not performed, the use of radiation combined with steroids 
has been shown to provide improved pain management and improved outcome when 
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compared to radiation alone (Loblaw, et al., 2005). In cases were surgery is planned, the use 
of preoperative EBRT is associated with an increase in local wound-related complications 
(Bilsky, et al., 2000; Itshayek, et al., 2010; Itshayek, et al., In press). 
Numerous EBRT protocols may be employed in the management of painful bone metastasis, 
including fractionated and single-fraction regimens. The dose ranges from 8 Gy delivered in 
a single fraction, up to a cumulative dose of 30–40 Gy administered over 3–4 weeks (Gerrard 
& Franks, 2004; Harel & Angelov, 2010). In a retrospective evaluation of treatment, 
comparing a single 8 Gy dose with several hypofractionated regimens in 1304 patients with 
spine metastases, there was no statistical difference for the various protocols in terms of 
patient survival, pain control, or side effects, however there were higher recurrence rates in 
patients treated with a lower cumulative dose (Rades, et al., 2005). 
 
Fig. 3. Treatment plan showing a map of the radiation fields for external beam radiation 
therapy. A 42-year-old male presented with low back pain and cauda equina syndrome due 
to metastatic synovial sarcoma to L4 (Fig. 2). Following laminectomy and resection, he 
suffered persistent axial back pain and proceeded to vertebral augmentation (Fig. 5). After 
augmentation ERBT was administered for tumor control. 
4.5.2 Stereotactic radiosurgery 
Stereotactic radiosurgery (SRS) is a new modality that is used in patients with spinal 
metastases in some centers. The use of stereotaxy enables deployment of high doses of 
radiation to inactivate or eradicate defined targets in the head or spine, even tumor found in 
close proximity to the spinal cord or other critical structures. SRS uses sophisticated 
computer algorithms to divide the lethal doses of radiation into multiple projections, 
focusing a very high dose in the target zone with rapid dose fall off, and thus minimal 
collateral damage to adjacent tissues (Moulding, et al., 2010). These systems are extremely 
accurate, with less than 1 mm deviation from the target. 
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The optimal SRS protocol is highly individual, and should take into account the tumor’s 
size, its pathological composure, and distance from the cord, as well as other radiosensitive 
organs. Data accumulating from an increasing number of studies suggests that SRS is a 
relatively safe, quick method to control spine metastases (Bilsky, et al., 2009). It provides 
excellent pain relief in most patients. In one study, significant pain relief was reported 6 
months after treatment in 91% of patients treated with the Cyberknife (Accuray, Sunnyvale 
CA, USA) (Chang, et al., 2009). Another study reported improved pain control and 
improved quality of life 1 year after treatment (Degen, et al., 2005). 
A possible side affect of spinal SRS is compression fracture, which may be attributed to 
rapid tumor lysis after radiation. These fractures can be managed conservatively or with 
pre-radiation vertebral augmentation (Gerszten, et al., 2005).  
 
Fig. 4. Treatment plan showing radiation fields for a stereotactic radiosurgery procedure. 
A 65-year-old male with renal cell carcinoma that was metastatic to L2 that was treated with 
single-shot SRS. 
4.6 Surgery 
4.6.1 Tumor decompression and instrumental stabilization 
The surgical treatment of spinal metastases has evolved significantly over the last 20 years, 
with mounting evidence of the value of surgery in the treatment of metastasis (Bilsky, et al., 
2009; Cole & Patchell, 2008; Harel & Angelov, 2010; Tomita, et al., 1997). Surgery was once 
limited to posterior laminectomy for the management of neurological decompression in SCC 
{Roy-Camille, 1990 #219}. With this philosophy, outcomes were mixed since most 
metastases are anterior to the cord and thus not directly accessible with posterior surgical 
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approaches. With advances in technique, new surgical approaches, and spinal 
instrumentation, patient outcomes have significantly improved, due to a combination of 
anterior tumor decompression and instrumental stabilization. The surgical approach is 
tailored, depending on the anatomic locations of metastases, aiming if possible to reach en 
block total resection of the tumor, the best possible outcome for the patient {Tomita, 2006 
#220}. Tumors anterior to the spinal cord are usually approached with a purely anterior 
approach, especially in the cervical spine, or through a posterolateral or lateral approach in 
the thoracic and lumbar spine. These approaches allow for anterior decompression with 
anterior column support, as well as posterior instrumented fusion for improved stability. 
Although laminectomy can help to increase the diameter of the spinal canal at the affected 
levels, it does not achieve immediate cord decompression and can lead to instability {Black, 
1996 #213; Camins, 2004 #221}.  
As in most procedures for the management of metastatic disease, the aim is not to provide a 
cure but rather to relieve pain, stabilize the spine, prevent neurological deterioration, and at 
times provide a pathological diagnosis (Choi, et al., 2010). In select cases, complete resection 
of a spinal metastasis can be performed, which can provide the best opportunity for long-
term local control and palliation in patients with isolated metastases or radioresistant 
tumors (Gallo & Donington, 2007). In cases where total resection cannot be achieved, 
stabilization and decompression provide a window of opportunity for other treatment 
modalities to take their course without jeopardizing the patients’ health. In two large 
cohorts of patients, surgery reduced pain, and improved physical function and quality of 
life in patients with symptomatic vertebral metastases at 12 month follow up and beyond, 
with an acceptable complication rate (Falicov, et al., 2006; Quan, et al., 2011). 
In cases of SCC, treatment should include corticosteroids, surgery, and radiotherapy along 
with aggressive systemic chemotherapy. Surgical decompression followed by radiotherapy 
was shown to be superior to radiotherapy alone in a study that was halted early after 
interim analysis demonstrated superior results in the surgery and radiotherapy group 
compared to the radiotherapy alone group (Patchell, et al., 2005). Patients treated with 
surgery plus radiotherapy had a median survival of 126 days with ambulation for 122 days, 
compared to a median 100 days survival and only 13 days ambulation in patients treated 
with EBRT alone. These findings were confirmed in a retrospective study conducted at our 
center (unpublished results). Patients who were operated had longer periods of ambulation 
relative to patients treated solely by radiotherapy. They also required lower doses and 
lighter pain medications. 
4.6.2 Vertebral augmentation using vertbroplasty and kyphoplasty 
Over the past two decades, percutaneous cement augmentation techniques have been 
developed for the treatment of spinal metastases and fractures. The two most common 
techniques are vertebroplasty and kyphoplasty. Vertebroplasty is a technique in which 
cement is injected into the vertebral body; kyphoplasty uses a balloon to create a void in the 
vertebrae into which the cement is injected. In a recent review comparing these techniques, 
pain scores for both the vertebroplasty and the kyphoplasty groups decreased significantly 
from preoperative values at 6-month follow-up (Liu, et al., 2010). The National Institute for 
Health and Clinical Excellence (NICE) guidelines (N.H.S., 2003; 2006) state that 
vertebroplasty or kyphoplasty should be considered for patients with vertebral metastases 
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when their pain is refractory to analgesia, or when there is evidence of vertebral body 
collapse, in cases where is no evidence of cord compression or spinal instability.  
 
     A     B          C 
Fig. 5. Vertebral augmentation. A 47-year-old male presented with persistent axial low back 
pain that was refractory to medical management following laminectomy and resection of an 
epidural mass from an L4 metastasis of a synovial sarcoma (see Figs. 2, 3). The patient 
underwent vertebral augmentation. (A) An OsseoFix implant (Alphatech Spine, Carsbad 
CA, USA) is inserted in an unexpanded configuration into the L4 vertebral body. (B) Once 
proper placement is confirmed on fluoroscopy, the implant is expanded. (C) The implant is 
filled with PMMA bone cement. Following augmentation the patient is pain free. 
5. Conclusions  
Back pain is one of the most prevalent medical problems, and is usually benign. However, 
in patients with a history of cancer, one must take extreme precautions to make sure that a 
metastatic spread of the tumor is not missed. Metastases may present as mechanical pain, 
radicular pain or weakness, or with myelopathy. Pain is usually unremitting and 
progressive.  
MRI is the gold standard for image-based diagnosis, with excellent depiction of soft tissue, 
including the spinal cord and nerve roots; CT provides optimal visualization of bony 
structures.  
Pain is the most common and earliest complaint, and sadly, it is undertreated in most 
patients. Most studies are not focused on pain control, but rather on the neurological status 
of the patient, while pain control is a secondary objective.  
Management of back pain in metastatic patients may involve a combination of pain 
medications, chemotherapy, radiation-based treatment, and surgery. Patient management 
thus requires the combined efforts of a multidisciplinary team, including oncologists, 
radiation oncologists, and spine surgeons. Treatment should be tailored to the needs of 
specific patients, based on their prognosis, neurological status, age, and primary pathology.  
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